← All organizations
Highest phase reached
Phase 4
First clinical trial
Jan 1, 2013First marketed drug
Jan 1, 2013First NDA
Nov 9, 2023Last known activity
Feb 6, 2026
Timeline
2000s
- Mar 30, 2009
inactivated japanese encephalitis vaccine— NDA Secondary Org
2020s
- Nov 9, 2023
Chikungunya Vaccine, Live— NDA Organization
Drugs by trial phase (21 distinct, 55 trials)
Phase 4 (1 own, 0 via acquisition)
Phase 3 (8 own, 1 via acquisition)
Phase 2 (3 own, 2 via acquisition)
Indications
Studied for
- Borrelia Infections
- Chikungunya Fever
- Clostridium Infections
- Diarrhea
- Encephalitis
- Encephalitis, Japanese
- Escherichia coli Infections
- Hepatitis
- Hepatitis A
- Hepatitis C
- Hepatitis C, Chronic
- Lyme Neuroborreliosis
- Pneumococcal Infections
- Pneumonia
- Pneumonia, Ventilator-Associated
- Pseudomonas Infections
- Virus Diseases
- Zika Virus Infection
Marketed drugs (2)
Subsidiaries (2 direct, 2 total across the full acquisition tree)
Recent trials (50)
- NCT07133178Lead sponsorPhase 3Feb 6, 2026
- NCT07133178OfficialPhase 3Feb 6, 2026
- NCT06334393Lead sponsorPhase 1Mar 25, 2024
- NCT06106581Lead sponsorPhase 2Dec 31, 2023
- NCT06106581Study chairPhase 2Dec 31, 2023
- NCT06028841Lead sponsorPhase 3Nov 30, 2023
- NCT06028841Study chairPhase 3Nov 30, 2023
- NCT05298644Lead sponsorPhase 2/Phase 3Oct 1, 2022
- NCT05298644Study chairPhase 2/Phase 3Oct 1, 2022
- NCT05477524CollaboratorPhase 3Aug 4, 2022
- NCT05364242Lead sponsorPhase 2/Phase 3May 9, 2022
- NCT05364242Study chairPhase 2/Phase 3May 9, 2022
- NCT04956224Lead sponsorPhase 3Aug 9, 2021
- NCT04956224Study chairPhase 3Aug 9, 2021
- NCT04864561Lead sponsorPhase 3Apr 26, 2021
Details
- Founded
- Lyon, FR Jan 1, 2013
- First NDA
- Nov 9, 2023
- Last known activity
- Feb 6, 2026
Designations held
- Breakthrough therapy
- Accelerated approval